Yong-Sung Kim

Professor

Ajou University

South Korea

Research Interests

Explore related searches

Professors in South Korea Professors in Immunology Immunology professors in South Korea

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Yong-Sung Kim is a faculty member at Ajou University in South Korea. His research areas encompass immunotherapy, particularly in enhancing the efficacy of cancer treatments and neutralizing antibodies against SARS-CoV-2 variants. Recent publications include work on bispecific T-cell engagers and the development of monoclonal antibodies tailored to target specific viral and cancer cell mechanisms.

Articles (14)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (2)

Keunok Jung

Research Assistant Professor

Ajou University Hospital

SOUTH KOREA

View details

Sang Taek Jung

Korea University

SOUTH KOREA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Yong-Sung Kim

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Enhancing the cytotoxicity of immunotoxins by facilitating their dissociation from target receptors under the reducing conditions of the endocytic pathway

Enhanced Omicron Variant Neutralization by a Human Antibody Tailored to Wild-Type and Delta-Variant SARS-CoV-2 RBDs

Harnessing SARS‐CoV‐2‐specific CD8+ T cells to kill target tumor cells for cancer immunotherapy

Engineering bispecific T-cell engagers to deplete eosinophils for the treatment of severe eosinophilic asthma

Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy

Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8+ T cells for cancer immunotherapy

Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity

Engineering a U-box of E3 ligase E4B through yeast surface display-based functional screening generates a variant with enhanced ubiquitin ligase activity

Affinity Maturation of a T-Cell Receptor-Like Antibody Specific for a Cytomegalovirus pp65-Derived Peptide Presented by HLA-A*02:01

Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity

MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants

Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Cancer

Engineering of an EpCAM-targeting cyclic peptide to improve the EpCAM-mediated cellular internalization and tumor accumulation of a peptide-fused antibody

Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.

Collaborators (2)

Keunok Jung

Sang Taek Jung

Make your next move.